Discovery, structure - Activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5734-5748

  Patnaik, Samarjit ^a   Zheng, Wei ^a   Choi, Jae H ^b   Motabar, Omid ^b   Southall, Noel ^a   Westbroek, Wendy ^b   Lea, Wendy A ^a   Velayati, Arash ^b   Goldin, Ehud ^b   Sidransky, Ellen ^b   Leister, William ^a   Marugan, Juan J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FIBROBLAST; GAUCHER DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYSOSOME; MALE; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MICE; MICE, INBRED C57BL; PERMEABILITY; PYRIMIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863083762     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300063b     Document Type: Article

References (52)

1. Beutler, E.; Grabowski, G. A. Gaucher Disease. In The Metabolic and Molecular Bases of Inherited Disease, 8 th ed.; Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds.; McGraw-Hill: New York, 2001; pp 3635-3668.
2. Germain, D. P. Gaucher's disease: a paradigm for interventional genetics Clin. Genet. 2004, 65, 77-86
3. Grabowski, G. A. Gaucher disease. Enzymology, genetics, and treatment Adv. Hum. Genet. 1993, 21, 377-441
4. Beutler, E.; Nguyen, N. J.; Henneberger, M. W.; Smolec, J. M.; McPherson, R. A.; West, C.; Gelbart, T. Gaucher disease: gene frequencies in the Ashkenazi Jewish population Am. J. Hum. Genet. 1993, 52, 85-88
5. Beck, M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy Hum. Genet. 2007, 121, 1-22
6. Grabowski, G. A. Phenotype, diagnosis, and treatment of Gaucher's disease Lancet 2008, 42, 1263-1271. Also see http://www.cerezyme.com
7. Beutler, E. Lysosomal storage diseases: natural history and ethical and economic aspects Mol. Genet. Metab. 2006, 25, 147-151
8. Pastores, G. M.; Giraldo, P.; Cherin, P.; Mehta, A. Goal-oriented therapy with miglustat in Gaucher disease Curr. Med. Res. Opin. 2009, 25, 23-37. Also see http://www.zavesca.com/patient-home.asp
9. Futerman1, A. H.; Sussman, J. L.; Horowitz, M.; Silman, I.; Zimran, A. New directions in the treatment of Gaucher disease Trends Pharmacol. Sci. 2004, 25, 147-151
10. Schiffmann, R.; Fitzgibbon, E. J.; Harris, C.; DeVile, C; Davies, E. H. Randomized, controlled trial of miglustat in Gaucher's disease type 3 Ann. Neurol. 2008, 64, 514-522
11. Montalvo, A. L.; Cariati, R.; Deganuto, M.; Guerci, V.; Garcia, R.; Ciana, G.; Bembi, B.; Pittis, M. G. Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease Mol. Genet. Metab. 2004, 81, 203-208
12. Hermans, M. M.; van Leenen, D.; Kroos, M. A.; Beesley, C. E.; Van der Ploeg, A. T.; Sakuraba, H.; Wevers, R.; Kleijer, W.; Michelakakis, H.; Kirk, E. P.; Fletcher, J.; Bosshard, N.; Basel-Vanagaite, L.; Besley, G.; Reuser, A. J. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype - phenotype correlation in glycogen storage disease type II Hum. Mutat. 2004, 23, 47-56
13. Reuser, A. J.; Kroos, M.; Willemsen, R.; Swallow, D.; Tager, J. M.; Galjaard, H. J. Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts Clin. Invest. 1987, 79, 1689-1699
14. Reuser, A. J.; Kroos, M.; Oude Elferink, R. P.; Tager, J. M. Defects in synthesis, phosphorylation, and maturation of acid alphaglucosidase in glycogenosis type II J. Biol. Chem. 1985, 260, 8336-8341
15. Schmitz, M.; Alfalah, M.; Aerts, J. M. F. G.; Naim, H. Y.; Zimmer, K.-P. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease Int. J. Biochem. Cell Biol. 2005, 37, 2310-2320
16. Ron, I.; Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity Hum. Mol. Genet. 2005, 14, 2387-2398
17. Fan, J.-Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity Trends Pharmacol. Sci. 2003, 24, 355-360
18. Morello, J. P.; Petäjä-Repo, U. E.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones: a new twist on receptor folding Trends Pharmacol. Sci. 2000, 21, 466-469
19. Sawkar, A. R.; Schmitz, M. S.; Zimmer, K.-P.; Reczek, D.; Edmunds, T.; Balch, W. E.; Kelly, J. W. Chemical chaperones and permissive temperatures alter the cellular localization of Gaucher disease associated glucocerebrosidase variants ACS Chem. Biol. 2006, 1, 235-251
20. Wei, R. R.; Hughes, H.; Boucher, S.; Bird, J. J.; Guziewicz, N.; Van Patten, S. M.; Qiu, H.; Qun Pan, C.; Edmunds, T. X-ray and biochemical analysis of N370S mutant human acid β-glucosidase J. Biol. Chem. 2011, 286, 299-308
21. Benito, J. M.; Fernández, J. M.; Mellet, C. O. Pharmacological chaperone therapy for Gaucher disease: a patent review Expert Opin. Ther. Pat. 2011, 21, 885-903
22. Fan, J.-Q.; Ishii, S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors FEBS J. 2007, 274, 4962-4971
23. Sawkar, A. R.; Cheng, W.-C.; Beutler, E.; Wong, C.-H.; Balch, W. E.; Kelly, J. W. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15428-15433
24. Yu, Z.; Sawkar, A. R.; Whalen, L. J.; Wong, C.-H.; Kelly, J. W. Isofagomine- and 2,5-anhydro-2,5-imino- d -glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention J. Med. Chem. 2007, 50, 94-100
25. Zhu, X.; Sheth, K. A.; Li, S.; Chang, H.-H.; Fan, J.-Q. Rational design and synthesis of highly potent β-glucocerebrosidase inhibitors Angew. Chem., Int. Ed. 2005, 44, 7450-7453
26. Aguilar, M.; Gloster, T. M.; Garcia-Moreno, M. I.; Mellet, C. O.; Davies, G. J.; Llebaria, A.; Casas, J.; Egido-Gabás, M.; Fernandez, J. M. G. Molecular basis for beta-glucosidase inhibition by ring-modified calystegine analogues ChemBioChem 2008, 9, 2612-2618
27. Egido-Gabás, M.; Canals, D.; Casas, J.; Llebaria, A.; Delgado, A. Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease ChemMedChem 2007, 2, 992-994
28. Compain, P; Martin, O. R.; Boucheron, C.; Godin, G.; Yu, L.; Ikeda, K.; Asano, N. Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease ChemBioChem 2006, 7, 1356-1359
29. Steet, R. A.; Chung, S.; Wustman, B.; Powe, A.; Do, H.; Kornfeld, S. A. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13813-13818
30. Amicus Therapeutics. Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera for Gaucher Disease. http://ir.amicustherapeutics. com/ReleaseDetail.cfm?ReleaseID=413437.
31. Zheng, W.; Padia, J.; Urban, D. J.; Jadhav, A.; Goker-Alpan, O.; Simeonov, A.; Goldin, E.; Auld, D.; LaMarca, M. E.; Inglese, J.; Austin, C. P.; Sidransky, E. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 13192-13197
32. Huang, W.; Zheng, W.; Urban, D. J.; Inglese, J.; Sidransky, E.; Austin, C. P.; Thomas, C. J. N 4-Phenyl modifications of N 2-(2-hydroxyl)ethyl-6- (pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease Bioorg. Med. Chem. Lett. 2007, 17, 5783-5789
33. Tropak, M. B.; Kornhaber, G. J.; Rigat, B. A.; Maegawa, G. H.; Buttner, J. D.; Blanchard, J. E.; Murphy, C.; Tuske, S. J.; Coales, S. J.; Hamura, Y.; Brown, E. D.; Mahuran, D. J. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry ChemoBioChem 2008, 9, 2650-2662
34. Goldin, E.; Zheng, W.; Motabar, O.; Southall, N.; Choi, J. H.; Marugan, J. J.; Austin, C. P.; Sidransky, E. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerberosidase PLoS One 2012, 7, e29861
35. Marugan, J. J.; Zheng, W.; Motabar, O.; Southall, N.; Goldin, E.; Westbroek, W.; Stubblefield, B. K.; Sidransky, E.; Aungst, R. A.; Lea, W. A.; Simeonov, A.; Leister, W.; Austin, C. P. Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity J. Med. Chem. 2010, 54, 1033-1058
36. Marugan, J. J.; Huang, W.; Motabar, O.; Zheng, W.; Xiao, J.; Patnaik, S.; Southall, N.; Westbroek, W.; Lea, W. A.; Simeonov, A.; Goldin, E.; DeBernardi, M. A.; Sidransky, E. Non-iminosugar glucocerebrosidase small molecule chaperones Med. Chem. Commun. 2012, 3, 56-60
37. Kuriyama, C.; Kamiyama, C.; Ikeda, K.; Sanae, F.; Kato, A.; Adachi, I.; Imahori, T.; Takahata, H.; Okamoto, T.; Asano, N. In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures Bioorg. Med. Chem. 2008, 16, 7330-7336
38. John, M.; Wendeler, M.; Heller, M.; Sandhoff, K.; Kessler, H. Characterization of human saposins by NMR spectroscopy Biochemistry 2006, 45, 5206-5216
39. Lieberman, R. L. A Guided tour of the structural biology of Gaucher disease: acid-β-glucosidase and saposin C. Enzyme Res. 2011, DOI 10.4061/2011/973231.
40. Vaccaro, A. M.; Salvioli, R.; Barca, A.; Tatti, M.; Ciaffoni, F.; Maras, B.; Siciliano, R.; Zappacosta, F.; Amoresano, A.; Pucci, P. Structural analysis of saposin C and B. Complete localization of disulfide bridges J. Biol. Chem. 1995, 270, 9953-9960
41. Urban, D. J.; Zheng, W.; Goker-Alpan, O.; Jadhav, A.; LaMarca, M. E.; Inglese, J.; Sidransky, E.; Austin, C. P. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high-throughput screening Comb. Chem. High Throughput Screening 2008, 11, 817-824
42. van Weely, S.; van den Berg, M.; Barranger, J. A.; Sa Miranda, M. C.; Tager, J. M.; Aerts, J. M. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease J. Clin. Invest. 1993, 91, 1167-1175
43. Sawkar, A. R.; D'Haeze, W.; Kelly, J. W. Therapeutic strategies to ameliorate lysosomal storage disorders: a focus on Gaucher disease Cell. Mol. Life Sci. 2006, 63, 1179-1192
44. Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C. P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries Proc. Natl. Acad. Sci. U S A. 2006, 103, 11473-11478
45. Nitz, T. J.; Salzwedel, K.; Finnegan, C.; Wild, C.; Brunton, S.; Flanagan, S.; Montalbetti, C.; Coulter, T. S.; Kimber, M.; Magaraci, F.; Johnston, D. Alpha-Unsubstituted Arylmethyl Piperazine Pyrazolo[1,5-a]pyrimidine Amide Derivatives. WO 2008/134035, 2008.
46. Huppatz, J. L. Systemic fungicides. The synthesis of pyrazolo[1,5- a ]pyrimidine analogues of carboxin Aust. J. Chem. 1985, 38, 221-230
47. Hayashi, Y.; Zama, K.; Abe, E.; Okino, N.; Inoue, T.; Ohno, K.; Ito, M. A sensitive and reproducible fluorescent-based HPLC assay to measure the activity of acid as well as neutral β-glucocerebrosidases Anal. Biochem. 2008, 283, 122-129
48. Schmitz, M.; Alfalah, M.; Aerts, J. M.; Naim, H. Y.; Zimmer, K. P. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease Int. J. Biochem. Cell Biol. 2005, 37, 2310-2320
49. Lieberman, R. L.; Wustman, B. A.; Huertas, P.; Powe, A. C., Jr.; Pine, C. W.; Khanna, R.; Schlossmacher, M. G.; Ringe, D.; Petsko, G. A structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease Nat. Chem. Biol. 2007, 3, 101-107
50. Stone, D. L.; Tayebi, N.; Orvisky, E.; Stubblefield, B.; Madike, V.; Sidransky, E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease Hum. Mutat. 2000, 15, 181-188
51. Jerabek-Willemsen, M.; Wienken, C. J.; Braun, D.; Baaske, P.; Duhr, S. Molecular interaction studies using microscale thermophoresis Assay Drug Dev. Technol. 2011, 9, 342-353
52. Marugan, J. J.; Zheng, W.; Motabar, O.; Southall, N.; Goldin, E.; Sidransky, E.; Aungst, R. A.; Liu, K.; Sadhukhan, S. K.; Austin, C. P. Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5- d ]pyrimidin-4(1 H)-one analogues as GAA activators Eur. J. Med. Chem. 2010, 45, 1880-1897